CLASS II ONGOING Drug recall · Reported 23 Jul 2025 · FDA Enforcement Report

Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg) recalled

Accord Healthcare is recalling Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), distributed nationwide in the US. The recall was initiated on 20 Jun 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #D2300087, Exp Date: 12/31/2025
NDC16729-447, 16729-458, 16729-448, 16729-449, 16729-451, 16729-450
UPC0316729447157, 0316729449151, 0316729452151, 0316729454155, 0316729453158, 0316729448154
Quantity recalled54,227 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0520-2025
FDA event ID
97103
Recalling firm
Accord Healthcare, Raleigh, NC
Manufacturer
Accord Healthcare Inc.
Classification
Class II
Status
Ongoing
Recall initiated
20 Jun 2025
FDA classified
14 Jul 2025
Reported
23 Jul 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

20 Jun 2025Recall initiated by company
14 Jul 2025Classified by FDA+24 days
23 Jul 2025Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Subpotent Drug: Assay below the approved specification

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 90-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-448-15

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Why was it recalled?

Subpotent Drug: Assay below the approved specification

Which lots are affected?

Lot #D2300087, Exp Date: 12/31/2025

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

6 other products · FDA event 97103

This product is part of a recall event; the main page for the event is Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg) recalled.

More recalls from Accord Healthcare

All 106

Other Levothyroxine recalls

All 145